Abstract Gastroenteropancreatic (GEP) endocrine tumors (ETs) are neoplasms showing different hormonal profiles and different clinical and prognostic features, which depend consistently on the site of origin. Histological features and general endocrine markers do not differentiate tumors in relation to their location, making it difficult to establish the site of origin of a GEP ET that has metastasized to the liver or lymph nodes. A sitespecific marker would be particularly useful in the examination of small specimens where there is not sufficient material for an extensive study of the hormonal expression. CDX2 is a transcription factor that has been recently proposed as a marker of intestinal adenocarcinomas. Our aim was to evaluate the immunohistochemical expression of CDX2 in normal tissues and in 184 formalin-fixed and paraffin-embedded ETs to verify whether it could be used to identify intestinal ETs with a high degree of sensitivity and specificity. Of these cases, 154 were primary tumors (99 GEP and 55 non-GEP tumors), 101 were well-differentiated endocrine tumors, and 53 were poorly differentiated endocrine carcinomas (PDECs). Of the cases, 30 were metastases from differently located ETs. Nuclear CDX2 immunoreactivity was found in all EC-cells (serotonin-producing cells), in about 10% of G-cells (gastrinproducing cells), in about 30% of GIP-cells (gastric inhibitory peptide cells) and in a few motilin-positive cells of the normal intestinal mucosa, while other gastrointestinal endocrine cell types were CDX2 negative. All midgut EC-cell tumors, their metastases, and two of three pancreatic EC-cell ETs were diffusely and intensely CDX2 positive. The other GEP ETs, their metastases, as well as the non-GEP ETs, were all CDX2 negative, with the exception of four PDECs, five gastrinomas and one pheochromocytoma, which were only focally positive. We conclude that CDX2 may be considered a sensitive and specific marker of midgut EC-cells and EC-cell tumors, and its expression may be useful in the diagnosis of metastases from occult ETs.
Introduction
Cdx2 is a homeobox gene that has been recently found to play a role in the development and differentiation of mammalian intestine [8, 24, 25] . The gene codifies a transcription factor protein named CDX2 [5] , which increases the expression of several gene products associated with mature intestinal epithelial cells [30] . This complex machinery of sequentially activated genes seems to decrease cellular replication and induce differentiation to mature intestinal epithelium [30] .
All recent published papers regarding the role and expression of CDX2 in intestinal epithelium have focused their attention on the exocrine component of the bowel mucosa. However, it is well known that there are several scattered endocrine cell types along the gut that, together with those located in the pancreas, form a large endocrine organ, generally referred to as the gastroenteropancreatic (GEP) endocrine system [27] . This system is remarkably heterogeneous and is composed of as many as 15 highly specialized endocrine cells, which show different hormonal profiles, physiological functions and site distribution [13, 27] . To the best of our knowledge, it is not known whether various endocrine cell types of the gut and pancreas express the CDX2 protein.
GEP endocrine tumors (ETs) form a heterogeneous group of neoplasms showing different hormonal profiles and different morphological, clinical and prognostic fea-tures, depending on the site of origin [13, 26] . According to the World Health Organization classification of ETs [27] , pure endocrine neoplasms are separated into two main categories: well-differentiated endocrine tumors (WDETs) and poorly differentiated endocrine carcinomas (PDECs). In histological preparations, PDECs are easily distinguished from WDETs because they show solid sheets composed of cells with high-grade atypia, hyperchromatic nuclei, a high nuclear/cytoplasmic ratio, a high mitotic rate and extensive necrosis. In contrast, WDETs are generally formed by uniform small/medium-sized cells with regularly shaped nuclei, arranged in trabeculae or solid nests, with low or no mitotic activity and no necrosis. The histopathological features do not differentiate tumors in relation to the site of origin, with the only exception of duodenal somatostatin-producing D-cell neoplasms, which show a prevalent pseudoglandular pattern of growth [6] . In routine surgical pathology practice, GEP ETs are often first discovered as liver or lymph-node metastases coming from an occult primary neoplasm. The diagnosis is frequently made on a small specimen, such as a needle biopsy, and there is often insufficient material to perform a complete immunohistochemical hormonal profile, which may be "per se" a good indicator of the primary tumor site (e.g., insulin for a pancreatic tumor). The endocrine nature of neoplasms is confirmed by the expression of general endocrine markers, such as chromogranins, synaptophysin and neuronspecific enolase, which, however, are not useful for identifying the location of the primary tumor. The presence of a clinical endocrine syndrome may help to identify the site of origin of a GEP tumor [27] . However, several neoplasms are nonfunctioning at a clinical level, and their identification is, therefore, frequently difficult.
It has recently been suggested that CDX2 protein expression is an important marker of colorectal adenocarcinomas [2, 31] , and it seems to be particularly useful for the differential diagnosis of primary lung adenocarcinomas and lung metastases from intestinal adenocarcinomas. As far as we aware, apart from GEP hormones, there is no other specific marker for intestinal endocrine tumors, and the expression of CDX2 protein in GEP endocrine neoplasms has only been investigated in preliminary studies [3, 14] .
The aim of the present investigation was to evaluate the expression of CDX2 in normal GEP endocrine cells and in a large series of intestinal and extra-intestinal endocrine tumors to verify whether CDX2 may be used as a marker of tumors of intestinal origin.
Materials and methods

Cases
The material used in this study was obtained from the files of the Department of Pathology of the Ospedale di Circolo-University of Insubria in Varese. The material consisted of 184 endocrine tumors from different sites, which are listed in Table 1, Table 2 and Table 3. Of the cases, 154 were primary tumors, while 30 neoplasms represented metastases to the liver (6 cases), lymph nodes (22 Table 1 Main clinicopathological features and CDX2 expression in gastroenteropancreatic well-differentiated endocrine tumors. WHO World Health Organization, B benign behavior, UB uncertain behavior, C well-differentiated carcinoma, type 1 gastric histamineproducing enterochromaffin-like (ECL)-cell tumor associated with chronic atrophic gastritis, type 3 sporadic gastric ECL-cell tumor, G-cell gastrin-producing cell, D-cell somatostatin-producing cell, GP gangliocytic paraganglioma, EC-cell serotonin-producing cell, L-cell glicentin-producing cell, A-cell glucagon-producing cell, PPcell pancreatic polypeptide-producing cell (Table 2 ) endocrine neoplasms. Of the tumors, 53 were PDECs, originating in the gut (25 cases), pancreas (2 cases) or non-GEP sites, including skin, lung, prostate and urinary bladder (Table 3 ). In addition, normal tissues from a variety of organs (gut, pancreas, thyroid, parathyroid, adrenal gland, skin, lung, prostate, urinary bladder) were also analyzed. All tissues were fixed in buffered formalin (formaldehyde 4% and acetate buffer 0.05 M) for 24 h and routinely embedded in paraffin wax. Sections 5-mm thick were stained with hematoxylineosin, alcian blue-periodic acid-Schiff and Grimelius' silver stain for the histopathological examination.
Immunohistochemistry
All tumors were characterized on the basis of their hormonal expression, evaluated using the antibodies listed in Table 4 . CDX2 expression was detected with the monoclonal antibody CDX2-88 (Biogenex) raised against a full-length CDX2 recombinant protein.
Immunohistochemistry was performed using the avidin-biotin complex procedure [10] , while colocalization studies were performed using double-label immunostains according to Mason et al. [20] or Lan et al. [15] . Specificity controls consisted of absorption of antibodies and antisera with 10-20 nM of their related antigens, substitution of the primary antibody with non-immune serum of the same species at the same dilution and use of control tissues with or without the pertinent antigen. The specificity and sensitivity of CDX2 immunostaining in detecting intestinal EC-cell (serotonin-producing cell) neoplasms was calculated as follows: specificity=true negatives/(true negatives+false positives); sensitivity=true positives/(true positives+ false negatives) [2, 12] . For detecting intestinal well-differentiated EC-cell tumors, false positives were defined as intestinal non-ECcell tumors or extraintestinal ETs showing CDX2 immunoreactivity, while false negatives were intestinal EC-cell neoplasms lacking CDX2. For detecting EC-cell tumors independent of the site of origin, false positives were defined as non-EC-cell tumors showing CDX2 immunoreactivity, while false negatives were EC-cell neoplasms lacking CDX2.
Results
Normal tissue
No CDX2 immunoreactivity was observed in normal lung, skin, prostate, urinary bladder, adrenal gland, thyroid gland, parathyroid glands, pancreas, esophagus or stomach, with the only exception being areas of intestinal metaplasia in gastric mucosa. Conversely, nuclear CDX2 immunoreactivity was found in epithelial cells of the small and large bowel. The staining was present in all exocrine cells of the villi and crypts, while cells of duodenal Brunner glands were negative or weakly stained. Double-label immunohistochemical stains revealed that only a fraction of chromogranin-A-positive intestinal endocrine cells were CDX2 positive. Using antibodies directed against specific hormones, it was possible to demonstrate that CDX2 nuclear staining was present in all serotonin-immunoreactive (IR) intestinal EC-cells (Fig. 1A) , in about 30% of duodenal GIP (gastric inhibitory peptide)-IR cells, in a minority (about 10%) of duodenal gastrin-IR G-cells (gastrin-producing cells) (Fig. 1B) and motilin-IR cells. The CDX2 immunostaining was strong in EC-cells, while it was rather weak in G-, GIP-, and motilin-cells. No CDX2 nuclear staining was found in somatostatin- (Fig. 1C) , cholecystokinin-, secretin-and glicentin-IR intestinal cells. All chromogranin-positive endocrine cells of the stomach, pancreas, lung, prostate, adrenal gland, thyroid, skin and paraganglia were CDX2 negative.
Endocrine tumors
The CDX2 expression in various endocrine GEP tumor types is summarized in Table 1 . Nuclear CDX2 immunoreactivity was mainly restricted to midgut EC-cell tumors (19/19 positive cases), in which the majority of cells were strongly positive ( Fig. 2A) . A strong CDX2 expression was also noted in all eight metastases (three nodal, three liver, two omental) from intestinal EC-cell WDECs (Fig. 2B, C) . In addition, two of three nonfunctioning pancreatic EC-cell tumors showed CDX2-positive cells, while the three rectal tumors composed of EC-cells were CDX2 negative. The other GEP WDETs studied (47 cases) were CDX2 negative (Fig. 3) , except for one PPcell (pancreatic polypeptide-producing cell) tumor and five gastrinomas, which had a few cells with a weak CDX2 immunoreactivity. Therefore, considering all nonmidgut GEP tumors, only 8 of 53 (15%) cases showed CDX2-positive cells; in addition, in these cases, the nuclear CDX2 staining was weaker and more focal than that observed in midgut EC-cell tumors. The six metastases from non-EC-cell WDECs [three from type-III ECL-cell (enterochromaffin-like cell) gastric tumors, one from a duodenal D-cell neoplasm and two from rectal tumors], such as the primary neoplasms, were completely negative for nuclear CDX2 expression. In addition to GEP cases, we investigated the expression of CDX2 in 29 WDETs and WDECs from different sites, including thyroid, parathyroid, carotid body, ear, adrenal gland and lung (Table 2) . With the exception of one pheochromocytoma showing a few CDX2-positive nuclei, all tumors were negative. The expression of CDX2 in 53 PDECs is summarized in Table 3 . Only 3 of 27 (11%) GEP cases, located respectively in the stomach, right colon and rectum, showed a nuclear CDX2 immunoreactivity in a few cells of both primary and respective metastases. Among PDECs located in organs outside the digestive system, only one large cell neuroendocrine carcinoma of the lung showed a few weak CDX2 immunoreactive cells (Fig. 4) . The three GEP tumors presented a component of serotonin-positive cells, which was lacking in the lung tumor. Metastases from CDX2-negative primary PDECs (14 cases) were completely CDX2 negative.
In this study, CDX2 had a specificity of 0.87 and a sensitivity of 0.90 in detecting intestinal well-differentiated EC-cell tumors. As for the identification of endocrine tumors expressing serotonin, apart from the tumor site and cell differentiation, CDX2 had a specificity of 0.93 and a sensitivity of 0.89.
Discussion
In the present study, we have investigated the immunohistochemical expression of CDX2 in normal tissues and in a large series of endocrine neoplasms from different sites, and we have proved that CDX2 is a good marker of intestinal EC-cells and related neoplasms.
CDX2 is a transcription factor, which is expressed by epithelial cells of the intestinal mucosa, playing a role in their differentiation both in fetal and adult tissues [30] . Although CDX2 expression in exocrine intestinal epithelial cells has been well documented, there are no previous studies that look at the localization of CDX2 protein in normal intestinal endocrine cells. Our results demonstrate that CDX2 is expressed in normal human intestinal endocrine cells and that it shows a specific distribution among the different intestinal endocrine cell types. In particular, CDX2 is expressed in all serotoninproducing intestinal EC-cells and in a small fraction of duodenal G-, GIP-and motilin-cells but not in other intestinal or extra-intestinal endocrine cell types. It is well known that other transcription factors show a specific distribution among GEP endocrine cells, and, for several of them, a role in endocrine cell differentiation has been demonstrated. The factors that have been mostly considered include neurogenin 3 [11] , pax4 and pax6 [16, 28, 29] . The findings of the present study raise the possibility that the CDX2 protein may play some roles in the regulation of the transcription of multiple intestinal genes, including those involved in EC-, G-, GIP-and motilin-cell differentiation.
An interesting approach to verify the role of CDX2 in the maturation and differentiation of serotonin-producing EC-cells would be the study of intestinal mucosa in null mutant cdx2 / mice. Unfortunately, as far as we know, the endocrine population in cdx2 / null mutant mice has been never investigated. This has been mainly due to the fact that the homozygous cdx2 / phenotype is embryo lethal in the perimplantation period [7] . However, some studies have been performed in heterozygous cdx2 +/ mice that develop polypoid lesions in the pericaecal region and proximal colon [4] . These polyps showed the histological features of gastric cardia and body mucosa and were completely negative for CDX2 expression. Endocrine cells in these lesions have not been examined.
After the initial hypothesis of the origin of GEP endocrine cells from the neural crest [22, 23] , chimeric models have shown a common embryologic origin of gut endocrine epithelial cells from the endoderm layer [1, 17] . In this context, CDX2 expression in both normal endocrine and exocrine intestinal cells and related neoplasms lends additional support to the hypothesis of the endodermal origin of both these cell types, considering also that the expression of this transcription factor is restricted to endoderm-derived tissues.
Our study of the expression of CDX2 in 184 endocrine tumors has demonstrated that the nuclear immunoreactivity was mainly restricted to GEP WDETs and, in particular, to midgut EC-cell tumors and to a few gastrinproducing G-cell neoplasms. These findings are in concurrence with data reported in recent papers [2, 21, 31] and in abstracts presented at the 2004 Vancouver USCAP meeting [3, 14, 18, 19] . All these papers conclude that CDX2 is mainly expressed by midgut WDETs. Unlike other studies, in which the functional immunophenotype has not been fully defined, in the present investigation, we have clearly demonstrated that, among midgut WDETs, EC-cell neoplasms of the ileum, appendix and right colon strongly express CDX2, mirroring the distribution of CDX2 in normal endocrine cells of the gut. Similarly, we have proved that CDX2 expression by gastrin-producing G-cell tumors reflects a biological characteristic of normal intestinal G-cells but not of gastric G-cells.
We found CDX2 expression in 5 of 24 (20%) pancreatic WDETs, represented by 2 gastrinomas and 3 nonfunctioning (2 EC-cell and 1 PP-cell) tumors, with a correlation of tumor cell type and CDX2 expression similar to that of intestinal WDETs. Lin et al. [18] did not find CDX2 immunoreactivity in the 30 pancreatic endocrine tumors analyzed, while Barbareschi et al. [3] have reported CDX2 positivity in 14 of 48 (29%) nonfunctioning pancreatic WDETs, and, interestingly, CDX2-positive tumors were more frequently found among malignant cases. In our cases of pancreatic WDETs, we did not find a similar trend. In the 14 paired samples of primary and metastatic WDETs analyzed, CDX2 expression was equal in both sites.
In our cases, intense nuclear positivity was restricted to metastases from ileal EC-cell tumors. Therefore, CDX2 immunoreactivity in a metastasis from an occult WDEC should first suggest an ileal origin of the primary neoplasm. Considering also that appendiceal EC-cell tumors are very rarely malignant [6] and that right colon EC-cell neoplasms are much less frequent than ileal EC-cell tumors, CDX2 immunohistochemistry may, therefore, be recommended in the study of small specimens of liver or lymph-node metastases for which the pathologist does not have sufficient material for an extensive hormonal immunoprofile that, in most cases, could help to identify the primary site of the tumor. It is important to underline that among GEP tumors, five of six gastrinomas also presented a CDX2 immunoreactivity. However, the pattern of CDX2 positivity observed in G-cell tumors was different from that found in EC-cell neoplasms, being weaker and focal.
The fact that CDX2 may be used as a marker to identify intestinal EC-cell neoplasms is also corroborated by our finding that endocrine tumors that arise outside the digestive system are CDX2 negative, with the exception of only one pheochromocytoma showing a focal positivity. In fact, we did not find any CDX2 immunoreactivity in lung carcinoids (seven cases) or small cell PDECs (nine cases). Among five large cell neuroendocrine carcinomas of the lung, one showed a few weak positive cells. These findings are in concordance with previously reported data [2, 3, 18, 21, 31] . As far as we know, there are no reports of CDX2 expression in non-GEP WDETs other than the lung, so it is not possible to compare our findings, which represent the first description demonstrating that endocrine tumors located in tissues outside the digestive system lack CDX2 immunoreactivity.
Our results prove that CDX2 is a less important marker of PDECs, being expressed in only four (7.5%) of the cases examined. Three tumors were located in the digestive system and, as in the majority of WDETs, showed a component of serotonin-positive cells (Table 3) . In previous studies, some authors [2, 31] investigated small cell lung carcinomas, and, interestingly, all but one cases were CDX2-negative. More recently, Barbareschi et al. [3] have found that 77% of intestinal and 42% of nonintestinal PDECs were CDX2 positive. The reason for these differing results is not clear. The low CDX2 expression that we observed in PDECs can be explained if one considers that CDX2 is a differentiation factor, important in maintaining the mature features of endocrine cells, and its loss may lead to an immature endocrine pattern. In this context, it is interesting to recall that CDX2 expression is inversely correlated with the grade of dysplasia in colorectal adenomas and with the grade of colorectal carcinomas, being less expressed in poorly differentiated adenocarcinomas [9] . In summary, this study demonstrates that CDX2 has a different expression among different endocrine cell types of the normal GEP system and among functionally wellcharacterized GEP endocrine tumors. CDX2 is expressed in normal EC-, G-, GIP-and motilin-cells of the intestinal tract, in all primary and metastatic well-differentiated ECcell tumors of the ileum, appendix and right colon and in a subset of duodenal and pancreatic G-cell and EC-cell tumors. CDX2 is expressed only focally in PDECs of the GEP system and is not found in PDECs of other sites.
